Imago BioSciences

Translating advances in epigenetics into therapeutics for hematologic diseases

Imago is developing therapeutics for hematologic diseases based on emerging insights into epigenetic regulation of disease pathways. Epigenetic proteins regulate expression of many (oftentimes hundreds) of downstream genes, and Imago is taking a targeted approach to address specific epigenetic alterations that can be drivers of disease.

Year of Investment

2014

Strategy

Life Sciences

Subsector

Development-Stage Therapeutics, Specialty Pharmaceuticals

Location

San Francisco, California